{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05438329",
            "orgStudyIdInfo": {
                "id": "DB-1305-O-1001"
            },
            "organization": {
                "fullName": "DualityBio Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors",
            "officialTitle": "A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "first-in-human-study-of-db-for-advanced-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-14",
            "studyFirstSubmitQcDate": "2022-06-24",
            "studyFirstPostDateStruct": {
                "date": "2022-06-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "DualityBio Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "BioNTech SE",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.",
            "detailedDescription": "This is a multicenter, open-label, multiple-dose, first in human (FIH) study. The study consists of two parts: Part 1 adopts an accelerated titration at first dose level followed with classic \"3+3\" design to identify the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D); Part 2 is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors at the MTD/the RP2D. This study will enroll subjects with advanced/unresectable, recurrent, or metastatic malignant solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 842,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "DB-1305/BNT325 Dose Level 1",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 1",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Level 2",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 2",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Level 3",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 3",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Level 4",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 4",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Level 5",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 5",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Level 6",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 6",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Level 7",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 7",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 in combination with pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 in combination with pembrolizumab",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Combination Product: Pembrolizumab"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 1",
                    "type": "EXPERIMENTAL",
                    "description": "subjects with Non-Small Cell Lung Cancer (NSCLC) with actionable genetic alterations (AGAs) who will receive DB-1305/BNT325 on either dose level 1 or dose level 2",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 2",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on either dose level 1 or dose level 2",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 3",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with OC who will receive DB-1305/BNT325 on either dose level 1 or dose level 2",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 4",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with BC who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 5",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with Triple-Negative Breast Cancer (TNBC) who have progressed on or after standard systemic treatments and without prior treatment of sacituzumab govitecan who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 6",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with TNBC with treatment failure on sacituzumab govitecan who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 7",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with EC who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 8",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with malignant mesothelioma will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 9",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with Cervical Cancer (CC) who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Expansion 10",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with pancreatic cancer who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 11",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with Castration-Resistant Prostate Cancer (CRPC) who will receive DB-1305/BNT325 on a selected dose level (RP2D)",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "DB-1305/BNT325 Dose Expansion 12",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with pembrolizumab",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Combination Product: Pembrolizumab"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Level 8",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 at Dose Level 8",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 in combination with BNT327",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects will receive DB-1305/BNT325 in combination with BNT327",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Drug: BNT327"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Expansion 13",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Drug: BNT327"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Expansion 14",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with NSCLC with AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Drug: BNT327"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Expansion 15",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with CC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Drug: BNT327"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Expansion 16",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with OC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Drug: BNT327"
                    ]
                },
                {
                    "label": "Experimental: DB-1305/BNT325 Dose Expansion 17",
                    "type": "EXPERIMENTAL",
                    "description": "Enrolled subjects with TNBC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327",
                    "interventionNames": [
                        "Drug: DB-1305/BNT325",
                        "Drug: BNT327"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DB-1305/BNT325",
                    "description": "Administered Injection of Vein (I.V.)",
                    "armGroupLabels": [
                        "DB-1305/BNT325 Dose Expansion 1",
                        "DB-1305/BNT325 Dose Expansion 11",
                        "DB-1305/BNT325 Dose Expansion 12",
                        "DB-1305/BNT325 Dose Expansion 2",
                        "DB-1305/BNT325 Dose Expansion 3",
                        "DB-1305/BNT325 Dose Expansion 4",
                        "DB-1305/BNT325 Dose Expansion 5",
                        "DB-1305/BNT325 Dose Expansion 6",
                        "DB-1305/BNT325 Dose Expansion 7",
                        "DB-1305/BNT325 Dose Expansion 8",
                        "DB-1305/BNT325 Dose Expansion 9",
                        "DB-1305/BNT325 Dose Level 1",
                        "DB-1305/BNT325 Dose Level 2",
                        "DB-1305/BNT325 Dose Level 3",
                        "DB-1305/BNT325 Dose Level 4",
                        "DB-1305/BNT325 Dose Level 5",
                        "DB-1305/BNT325 Dose Level 6",
                        "DB-1305/BNT325 Dose Level 7",
                        "DB-1305/BNT325 in combination with pembrolizumab",
                        "Experimental: DB-1305/BNT325 Dose Expansion 10",
                        "Experimental: DB-1305/BNT325 Dose Expansion 13",
                        "Experimental: DB-1305/BNT325 Dose Expansion 14",
                        "Experimental: DB-1305/BNT325 Dose Expansion 15",
                        "Experimental: DB-1305/BNT325 Dose Expansion 16",
                        "Experimental: DB-1305/BNT325 Dose Expansion 17",
                        "Experimental: DB-1305/BNT325 Dose Level 8",
                        "Experimental: DB-1305/BNT325 in combination with BNT327"
                    ],
                    "otherNames": [
                        "DB-1305/BNT325 for Injection"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Pembrolizumab",
                    "description": "Administered I.V.",
                    "armGroupLabels": [
                        "DB-1305/BNT325 Dose Expansion 12",
                        "DB-1305/BNT325 in combination with pembrolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "BNT327",
                    "description": "Administered I.V.",
                    "armGroupLabels": [
                        "Experimental: DB-1305/BNT325 Dose Expansion 13",
                        "Experimental: DB-1305/BNT325 Dose Expansion 14",
                        "Experimental: DB-1305/BNT325 Dose Expansion 15",
                        "Experimental: DB-1305/BNT325 Dose Expansion 16",
                        "Experimental: DB-1305/BNT325 Dose Expansion 17",
                        "Experimental: DB-1305/BNT325 in combination with BNT327"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.",
                    "description": "Percentage of participants in Part 1 with DLTs",
                    "timeFrame": "up to 21 days after Cycle 1 Day 1"
                },
                {
                    "measure": "Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.",
                    "description": "Percentage of participants with TEAEs in Part 1 graded according to NCI CTCAE v5.0",
                    "timeFrame": "Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first."
                },
                {
                    "measure": "Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.",
                    "description": "Percentage of Participants with SAEs in Part 1 graded according to NCI CTCAE v5.0",
                    "timeFrame": "Up 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first."
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD) of DB-1305/BNT325",
                    "description": "MTD on the data collected during Part 1",
                    "timeFrame": "At the end of Cycle 1 (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1: RP2D of DB-1305/BNT325",
                    "description": "RP2D of DB-1305/BNT325 based on the data collected during Part 1",
                    "timeFrame": "From first study treatment administration until the initiation of Phase 2a, approximately up to 12 months."
                },
                {
                    "measure": "Phase 2a: Percentage of Participants with TEAEs as assessed by CTCAE v5.0.",
                    "description": "Percentage of participants with TEAEs in Part 2 graded according to NCI CTCAE v5.0",
                    "timeFrame": "Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first."
                },
                {
                    "measure": "Phase 2a: Percentage participants with SAEs as assessed by CTCAE v5.0.",
                    "description": "Percentage of participants with SAEs in Part 2 graded according to NCI CTCAE v5.0",
                    "timeFrame": "Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first."
                },
                {
                    "measure": "Phase 2a: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.",
                    "description": "The percentage of subjects who had a best response rating of CR and PR",
                    "timeFrame": "Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1: ORR will be determined from tumor assessments by investigator per RECIST 1.1",
                    "description": "Phase 1: ORR will be determined from tumor assessments by investigator per RECIST 1.1",
                    "timeFrame": "with 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: duration of response (DoR) will be determined from tumor assessments by investigator per RECIST 1.1",
                    "description": "Phase 1 \\& Phase 2a: duration of response (DoR) will be determined from tumor assessments by investigator per RECIST 1.1",
                    "timeFrame": "with 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: disease-control rate (DCR)",
                    "description": "Phase 1 \\& Phase 2a: disease-control rate (DCR)",
                    "timeFrame": "with 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: time to response (TTR)",
                    "description": "Phase 1 \\& Phase 2a: time to response (TTR)",
                    "timeFrame": "with 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: progression free survival (PFS) will be determined from tumor assessments by investigator per RECIST 1.1",
                    "description": "Phase 1 \\& Phase 2a: progression free survival (PFS) will be determined from tumor assessments by investigator per RECIST 1.1",
                    "timeFrame": "with 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: overall survival (OS)",
                    "description": "Phase 1 \\& Phase 2a: overall survival (OS)",
                    "timeFrame": "with 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: Pharmacokinetic parameters: (the area under the concentration-time curve from the time zero to the last quantifiable concentration [AUC0-last] of DB-1305/BNT325",
                    "description": "Phase 1 \\& Phase 2a: Pharmacokinetic parameters: (the area under the concentration-time curve from the time zero to the last quantifiable concentration \\[AUC0-last\\] of DB-1305/BNT325",
                    "timeFrame": "within 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: Pharmacokinetic parameters: the area under the concentration-time curve from time 0 to tau [AUC0-tau] of DB-1305/BNT325",
                    "description": "Phase 1 \\& Phase 2a: Pharmacokinetic parameters: the area under the concentration-time curve from time 0 to tau \\[AUC0-tau\\] of DB-1305/BNT325",
                    "timeFrame": "within 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: peak observed concentration [Cmax] of DB-1305/BNT325",
                    "description": "Phase 1 \\& Phase 2a: peak observed concentration \\[Cmax\\] of DB-1305/BNT325",
                    "timeFrame": "within 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: Pharmacokinetic parameters: time to Cmax [Tmax] of DB-1305/BNT325",
                    "description": "Phase 1 \\& Phase 2a: Pharmacokinetic parameters: time to Cmax \\[Tmax\\] of DB-1305/BNT325",
                    "timeFrame": "within 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: Pharmacokinetic parameters: trough concentration [Ctrough] of DB-1305/BNT325",
                    "description": "Phase 1 \\& Phase 2a: Pharmacokinetic parameters: trough concentration \\[Ctrough\\] of DB-1305/BNT325",
                    "timeFrame": "within 8 cycles (each cycle is 21 days)"
                },
                {
                    "measure": "Phase 1 & Phase 2a: anti-drug antibody (ADA) prevalence: the proportion of subjects who are ADA positive at any point in time (at baseline and post-baseline). ADA incidence: the proportion of subjects having treatment-emergent ADA.",
                    "description": "Phase 1 \\& Phase 2a: anti-drug antibody (ADA) prevalence: the proportion of subjects who are ADA positive at any point in time (at baseline and post-baseline). ADA incidence: the proportion of subjects having treatment-emergent ADA.",
                    "timeFrame": "within 8 cycles (each cycle is 21 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adults (defined as \u2265 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).\n* Histologically or cytologically confirmed unresectable advanced/ metastatic solid tumors who have relapsed or progressed on or after standard systemic treatments or for which no standard treatment is available.\n* At least one measurable lesion as assessed by the investigator according to RECIST version 1.1 criteria.\n* Has a life expectancy of \u2265 3 months.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.\n* Has Left Ventricular Ejection Fraction (LVEF) \u2265 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.\n* Has adequate organ functions within 7 days prior to Day 1 of Cycle 1.\n* Has adequate treatment washout period prior to Day 1 of Cycle 1.\n* Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of Trop-2 level and other biomarkers if not contraindicated.\n* Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.\n\nExclusion Criteria:\n\n* Has a medical history of symptomatic congestive heart failure (CHF) (New York Heart Association \\[NYHA\\] classes II-IV) or serious cardiac arrhythmia requiring treatment.\n* Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.\n* Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \\> 470 millisecond (ms) in males and females based on a 12-lead electrocardiogram (ECG) in triplicate.\n* Has a medical history of non-infectious Interstitial Lung Diseases (ILD)/pneumonitis or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Has a lung-specific intercurrent clinically significant illness.\n* Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals.\n* Subjects have human immunodeficiency virus (HIV) infection with acquired immune deficiency syndrome (AIDS) defining illness are not eligible for enrollment; However, subjects have had HIV infection with a cluster of differentiation 4 (CD4)+ T cell count \\> 350 cells/\u00b5L and no history of an AIDS-defining illness are eligible for entry.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tyler McCullars",
                    "role": "CONTACT",
                    "phone": "(404) 954-1826",
                    "email": "tyler.mccullars@tigermedgrp.com"
                },
                {
                    "name": "Cathy Li",
                    "role": "CONTACT",
                    "phone": "201-503-5410",
                    "email": "cathy.li@dualitybiologics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lily Hu",
                    "affiliation": "DualityBio Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Site 103",
                    "status": "RECRUITING",
                    "city": "Cerritos",
                    "state": "California",
                    "zip": "90703",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Omkar Marathe, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.85835,
                        "lon": -118.06479
                    }
                },
                {
                    "facility": "Site 108",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aaron E. Lisberg, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "D&H Cancer Research Center Llc",
                    "status": "RECRUITING",
                    "city": "Margate",
                    "state": "Florida",
                    "zip": "33063",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "DAVID KAHN, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.24453,
                        "lon": -80.20644
                    }
                },
                {
                    "facility": "Site 109",
                    "status": "RECRUITING",
                    "city": "Plantation",
                    "state": "Florida",
                    "zip": "33322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Harshad Amin, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.13421,
                        "lon": -80.23184
                    }
                },
                {
                    "facility": "BRCR Medical Center Inc.",
                    "status": "RECRUITING",
                    "city": "Tamarac",
                    "state": "Florida",
                    "zip": "33321",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chintan Gandhi, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.21286,
                        "lon": -80.24977
                    }
                },
                {
                    "facility": "Site 106",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hirva Mamdani, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Site 102",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria Michelle Rubinstein, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Site 101",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nashat Y. Gabrail, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Nashat Y. Gabrail, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                },
                {
                    "facility": "Site 105",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erika Paige Hamilton, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Site 110",
                    "status": "RECRUITING",
                    "city": "Arlington",
                    "state": "Texas",
                    "zip": "76017",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gerald Edelman, MD, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.73569,
                        "lon": -97.10807
                    }
                },
                {
                    "facility": "Site 104",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Senthil Damodaran, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Site 107",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Spira, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Site 211",
                    "status": "RECRUITING",
                    "city": "Bengbu",
                    "state": "Anhui",
                    "zip": "233099",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Dianming Li, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.94083,
                        "lon": 117.36083
                    }
                },
                {
                    "facility": "Site 217",
                    "status": "RECRUITING",
                    "city": "Hefei",
                    "state": "Anhui",
                    "zip": "230031",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Zhihong Zhang, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.86389,
                        "lon": 117.28083
                    }
                },
                {
                    "facility": "Site 213",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Fuzhou",
                    "state": "Fujian",
                    "zip": "350001",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Xiangqi Chen, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.06139,
                        "lon": 119.30611
                    }
                },
                {
                    "facility": "Site 209",
                    "status": "RECRUITING",
                    "city": "Nanning",
                    "state": "Guangxi",
                    "zip": "531200",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Weimin Xie, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.81667,
                        "lon": 108.31667
                    }
                },
                {
                    "facility": "Site 221",
                    "status": "RECRUITING",
                    "city": "Guigang",
                    "state": "Guanxi",
                    "zip": "537100",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Yan Wei",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 23.09639,
                        "lon": 109.60917
                    }
                },
                {
                    "facility": "Site 202",
                    "status": "RECRUITING",
                    "city": "Zhengzhou",
                    "state": "Henan",
                    "zip": "450000",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Min Yan, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.75778,
                        "lon": 113.64861
                    }
                },
                {
                    "facility": "Site 205",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Wuhan",
                    "state": "Hubei",
                    "zip": "430021",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Xiaorong Dong, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.58333,
                        "lon": 114.26667
                    }
                },
                {
                    "facility": "Site 208",
                    "status": "RECRUITING",
                    "city": "Ganzhou",
                    "state": "Jiangxi",
                    "zip": "341006",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Hua Yang, MD",
                            "role": "CONTACT"
                        }
                    ]
                },
                {
                    "facility": "Site 201",
                    "status": "RECRUITING",
                    "city": "Changchun",
                    "state": "Jilin",
                    "zip": "130012",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Ying Cheng, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.88,
                        "lon": 125.32278
                    }
                },
                {
                    "facility": "Site 210",
                    "status": "RECRUITING",
                    "city": "Shenyang",
                    "state": "Liaoning",
                    "zip": "110042",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Tao Sun, Doctor",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.79222,
                        "lon": 123.43278
                    }
                },
                {
                    "facility": "Site 216",
                    "status": "RECRUITING",
                    "city": "Jinan",
                    "state": "Shandong",
                    "zip": "250117",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Yuping Sun, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.66833,
                        "lon": 116.99722
                    }
                },
                {
                    "facility": "Site 212",
                    "status": "RECRUITING",
                    "city": "Linyi",
                    "state": "Shandong",
                    "zip": "276304",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Jianhua Shi, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.06306,
                        "lon": 118.34278
                    }
                },
                {
                    "facility": "Site 207",
                    "status": "RECRUITING",
                    "city": "Shanghai",
                    "state": "Shanghai",
                    "zip": "201315",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Jian Zhang, Doctor",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.22222,
                        "lon": 121.45806
                    }
                },
                {
                    "facility": "Site 206",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chengdu",
                    "state": "Sichuan",
                    "zip": "611135",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Lu Li, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.66667,
                        "lon": 104.06667
                    }
                },
                {
                    "facility": "Site 203",
                    "status": "RECRUITING",
                    "city": "Tianjin",
                    "state": "Tianjin",
                    "zip": "300060",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Chen Wang, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.14222,
                        "lon": 117.17667
                    }
                },
                {
                    "facility": "Site 220",
                    "status": "RECRUITING",
                    "city": "Taizhou",
                    "state": "Zhejiang",
                    "zip": "317004",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Dongqing Lv, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.49069,
                        "lon": 119.90812
                    }
                },
                {
                    "facility": "Site 219",
                    "status": "RECRUITING",
                    "city": "Guangzhou",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Haiyan Tu",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 23.11667,
                        "lon": 113.25
                    }
                },
                {
                    "facility": "BRCR GLOBAL Puerto Rico LLC.",
                    "status": "RECRUITING",
                    "city": "Mayaguez",
                    "zip": "00682",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Maryangely Moreno Campa, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.20107,
                        "lon": -67.13962
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M287620",
                    "name": "Sacituzumab govitecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}